HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Shenzhen Mindray Bio-Medical Electronics - The Future Performance Is Worth Looking Forward To

Pre-IPO Lepu Biopharma - There Are Still Many Uncertainties

Microport Scientific (853.HK) - It Is a Good Time to See Some Concerns

Chongqing Zhifei Biological Products (300122.CH) - Could Zhifei Support Its Valuation?

Industry Report: Insights on China IVD Industry - The POCT Market

Industry Report - Insights on China IVD Industry

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<p>Recently, <a href="https://www.smartkarma.com/entities/autobio-diagnostics-co-ltd" target="_blank" data-smartkarma-citation="entities:30185:1" rel="noopener">Autobio Diagnostics Co Ltd (603658 CH)</a> released the 2020 and 2021Q1 financial results. In 2020, the revenue was RMB2.98 billion, up 11.15% YoY. Net income was RMB757 million, down 3.79% YoY. In 2021Q1, Autobio achieved revenue of RMB817 million, up 48.44% YoY, and net income was RMB175 million, up 91.23% YoY. Due to the COVID-19, the performance of Autobio was affected in 2020, but the sales recovered gradually quarter by quarter. In 2021Q1, the domestic pandemic was basically stable with occasional regional recurrence, and the frequency of routine diagnosis and treatment in medical institutions recovered to about 80%-90% of the normal situation, so Autobio also achieved a rapid growth. Obviously, the Company is gradually getting rid of the adverse impact brought by COVID-19, and its leading position in IVD (chemiluminescence) has not changed. With the recovery of routine diagnosis and treatment in medical institutions, Autobio's performance is expected to get back on track.</p>

Recently, Autobio Diagnostics Co Ltd (603658 CH) released the 2020 and 2021Q1 financial results. In 2020, the revenue was RMB2.98 billion, up 11.15% YoY. Net income was RMB757 million, down 3.79% YoY. In 2021Q1, Autobio achieved revenue of RMB817 million, up 48.44% YoY, and net income was RMB175 million, up 91.23% YoY. Due to the COVID-19, the performance of Autobio was affected in 2020, but the sales recovered gradually quarter by quarter. In 2021Q1, the domestic pandemic was basically stable with occasional regional recurrence, and the frequency of routine diagnosis and treatment in medical institutions recovered to about 80%-90% of the normal situation, so Autobio also achieved a rapid growth. Obviously, the Company is gradually getting rid of the adverse impact brought by COVID-19, and its leading position in IVD (chemiluminescence) has not changed. With the recovery of routine diagnosis and treatment in medical institutions, Autobio's performance is expected to get back on track.

Shenzhen Mindray Bio-Medical Electronics (300760 CH)

Autobio Diagnostics (603658.CH) - The Turning Point Is Quietly Approaching